Evaluation of mineralized plasmatic matrix on augmentation of bone resorption

Abstract :

Bone resorption is created by different etiological factors, such as tumors, infections, and trauma. When defects are too large and healing is not possible in a spontaneous way, the defect is called a critical size defect, which is defined as the smallest size of an intra-osseous wound that will not heal spontaneously during the lifetime of the individual. This study was conducted to evaluate the use of a mineralized plasmatic matrix versus bone graft alone or in the augmentation of bony cavities in animals. Ten adult male dogs ranging in age from 12 months to 18 months with a mean weight of ten kilograms were used in this study. Bone cavities were made in the tibia of each animal. The upper holes were implanted with a bovine bone material substitute the medial holes were implanted with a mineralized plasmatic matrix and the lower holes were left free from any implant material acting as control. The dogs were euthanized at 2, 4, and 6 weeks and prepared for H and E stain and trichrome stain. The healing process of bone cavities implanted with mineralized plasmatic matrix was better compared to cavities filled with bone grafts and those left to heal spontaneously. Mineralized plasmatic matrix facilitates graft application, in its stabilization, and improves cell penetration into the graft.

References

1. Steele D G, Bramblett CA (1988) The anatomy and biology of the human skeleton. Texas A & M University Press. 4: 300-302. ISSN: 978-0-89096-326-5
2. Burchardt H, Enneking WF (1978) Transplantation of bone. The Surgical Clinics of North America. 58 (2): 403-427. doi: 10.1016/s0039-6109(16)41492-1
3. Kubler A, Neugebauer J, Hwan J, Scheer M, Zoller JE (2004) Growth and proliferation of human osteoblast on different bone graft substitutes, an in vitro study. Journal of Implant Dentistry. 13 (2): 171-179. doi: 10.1097/01.id.0000127522.14067.11
4. McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. The new England Journal of Medicine. 365: 2205-2219. 365(23):2205-19. doi: 10.1056/NEJMra1004965
5. Scott DL, Wolfe F, Huizinga T (2010) Rheum arthritis. Lancet. 376 (9746): 1094-1108. doi: 10.1016/S0140-6736(10)60826-4
6. Van O, Osterhout M, Bajema I, Levarht EW, Toes RE, Huizinga TW, van Laar J (2008) Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis and Rheumatism. 58 (1): 53-60. doi: 10.1002/art.23148
7. Markkuhakala SA, Risteli L, Risteli J (1996) Increased type I collagen degradation is associated with a need for total joint replacement surgery in rheumatoid arthritis. Annal of the Rheum Diseases. 55 (2): 147-148. doi: 10.1136/ard.55.2.147-a
8. Hakala M, Risteli L, Manelius J, Nieminen P, Risteli J (1993) Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Annals of the Rheumatic Diseases. 52 (12): 866-869. doi: 10.1136/ard.52.12.866
9. Peel N, Eastell R, Russell G (1992) Markers of bone and collagen breakdown in early inflammatory arthritis. Bailliere's Clinical Rheumatology. 6 (2): 351-372. doi: 10.1016/s0950-3579(05)80179-7
10. Choukroun J, Adda F, Schoeffer C, Vervelle A (2001) The opportunity in perio-implantology: The PRF. Implant dentistry. 42: 55-62. Corpus ID: 221331409
11. Sharma A, Pradeep AR (2011) Treatment of 3-wall intra bony defects in patients with chronic periodontitis with autologous platelet rich fibrin a randomized controlled clinical trial. Journal Periodontology. 82 (12): 1705-1712. doi: 10.1902/jop.2011.110075
12. Thorat M, Pradeep AR, Pallavi B (2011) Clinical effect of autologous platelet-rich fibrin in the treatment of intra-bony defects: a controlled clinical trial. Journal of Clinical Periodontology. 38 (10): 925-932. doi: 10.1111/j.1600-051X.2011.01760.x
13. Ehrenfest DM D, Diss A, Odin G, Doglioli P, Hippolyte MP, Charrier JB (2009) In vitro effects of Choukroun’s PRF (platelet-richfibrin) on human gingival fibroblasts, dermal prekeratinocytes, preadipocytes, and maxillofacial osteoblasts in primary cultures. Oral Surgery, Oral Medicine, Oral Pathology Oral Radiology and Endodontics. 108 (3): 341-352. doi: 10.1016/j.tripleo.2009.04.020
14. Ehrenfest DMD, de Peppo GM, Doglioli P, Sammartino G (2009) Slow release of growth factors and thrombospondin-1 in Choukroun’s platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors. 27 (1): 63-69. doi: 10.1080/08977190802636713
15. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B (2006) Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates? Oral Surgery, Oral Medicine, Oral Pathology Oral Radiology and Endodontics. 101 (3): e51-55. doi: 10.1016/j.tripleo.2005.07.010
16. Moojen DJ, Everts PA, Schure RM, Overdevest EP, van Zundert A, Knape JT, Castelein RM, Creemers LB, Dhert WJ (2008) Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. Journal of Orthopaedic Research. 26 (3): 404-410. doi: 10.1002/jor.20519
17. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis and Rheumatism. 48 (10): 2741-2749. doi: 10.1002/art.11223
18. Egerer K, Feist E, Burmester GR (2009) The serological diagnosis of rheumatoid arthritis: antibodies to citrullinated antigens. Dtschsches Arzteblatt International. 106: 159-163. doi: 10.3238/arztebl.2009.0159. doi: 10.1002/art.11223
19. Hardy R, Cooper, MS (2009) Bone loss in inflammatory disorders. The Journal of Endocrinology. 201 (3): 309-320. doi: 10.1677/JOE-08-0568
20. Wang Y, Kristan J, Hao L, Lenkoski CS, Shen Y, Matis LA (2000) A role for complement in antibody-mediated inflammation: C5-Deficient DBA/1 mice are resistant to collagen-induced arthritis. Journal of Immunology. 164: 4340-4347. doi: 10.4049/jimmunol.164.8.4340
21. Stuart JM, Watson WC, Kang AH (1988) Collagen autoimmunity and arthritis. FASEB Journal. 2 (14): 2950-2956. doi: 10.1096/fasebj.2.14.3053308
22. Tsai CH, Shen SY, Zhao JH, Chang YC (2009) Platelet-rich fibrin modulates cell proliferation of human periodontally related cells in vitro. Journal of Dental Sciences. 4 (3): 130-135. doi.org/10.1016/S1991-7902(09)60018-0
23. Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dhoan SL, Dhoan AJ, Mouhyi J, Dohan DM (2006) Platelet-rich fibrin (PRF): a second-generation platelet concentrate, part IV: clinical effects on tissue healing. Oral Surgery, Oral Medicine, Oral Pathology Oral Radiology and Endodontics. 101 (3): e56-60. doi: 10.1016/j.tripleo.2005.07.011
24. Zhao JH, Tsai CH, Chang YC (2011) Clinical and histologic evaluation of healing in an extraction socket filled with platelet-rich fibrin. Journal of Dental Sciences. 6 (2): 116-122. doi.org/10.1016/j.jds.2011.03.004
25. Mazor Z, Horowitz RA, Del Corso M, Prasad HS, Rohrer MD, Ehrenfest DMD (2009) Sinus floor augmentationwith simultaneous implant placement using Choukroun’s platelet-rich fibrin as the sole grafting material: a radiologic and histologic study at 6 months. Journal of Periodontology. 80 (12): 2056-2064. doi: 10.1902/jop.2009.090252
26. Saluja H, Dehane V, Mahindra U (2011) Platelet-rich fibrin. A second generation platelet concentrate and a new friend of oral and maxillofacial surgeons. Annals of Maxillofacial Surgery. 1 (1): 53-57. doi: 10.4103/2231-0746.83158
27. Saffarzadeh A, Gauthier O, Bilban M, Bagot D, Arc M, Daculsi G (2009) Comparison of two bone substitute biomaterials consisting of a mixture of fibrin sealant (Tisseel) and MBCP (TticOs) with an autograft in sinus left surgery in sheep. Clinical Oral Implants Research. 20 (10): 1133-1139. doi: 10.1111/j.1600-0501.2009.01738.x
28. Kim BJ, Kwon TK, Baek HS, Hwang DS, Kim CH, Chung IK, Jeong JS, Shin SH (2012) A comparative study of the effectiveness of sinus bone grafting with recombinant human bone morphogenetic protein 2-coated tricalcium phosphate and platelet-rich fibrin-mixed tricalcium phosphate in rabbits. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 113 (5): 583-592. doi: 10.1016/j.tripleo.2011.04.029
29. Metzler P, von Wilmowsky C, Zimmermann R, Wiltfang J, Schlegel KA (2012) The effect of current used bone substitution materials and platelet-rich plasma on periosteal cells by ectopic site implantation: an in-vivo pilot study. Journal of Cranio-maxillo-facial Surgery. 40: 409-415. doi: 10.1016/j.jcms.2011.07.012
30. Stromqvist B (1984) Hip fracture in rheumatoid arthritis. Acta Orthopaedica Scandinavica. 55 (6): 624-628. doi: 10.3109/17453678408992409
31. Marukawa E, Oshina H, Lino G, Morita K, Omura K (2011) Reduction of bone resorption by the application of platelet-rich plasma (PRP) in bone grafting of the alveolar cleft. Journal of Cranio-maxillo-facial Surgery. 39 (4): 278-283. doi: 10.1016/j.jcms.2010.04.017
32. Ralis ZA, Watkins G (1992) Modified tetrachrome method for osteoid and defectively mineralized bone in paraffin sections. Biotechnic and Histochemistry. 67 (6): 339-345. doi: 10.3109/10520299209110046
33. Sinclair S, William R Walsh WR (2022) Characterization of costal cartilage allografts. ANZ Journal of Surgery. 92 (9): 2274-2279. doi: 10.1111/ans.17967
34. Claes L, Reckngel S, Ignatius A (2012) Fracture healing under healthy and inflammatory conditions. Nature Reviews. Rheumatology. 8 (3): 133-114. doi: 10.1038/nrrheum.2012.1
35. Muire PJ, Lofgren AL, Shiels SM, Wenke JC (2023) Fracture healing in a polytrauma rat model is influenced by mtDNA:cGAS complex mediated pro-inflammation. Journal of Experimental Orthopedics. 10 (1): 90. doi: 10.1186/s40634-023-00637-5

Citation :

Abokrias and Aldarewesh (2023) Evaluation of mineralized plasmatic matrix on augmentation of bone resorption. Mediterr J Pharm Pharm Sci. 3 (3): 51-59. https://doi.org/10.5281/zenodo.8390130